HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 29, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

March 30, 2022

Conditions
Breast Cancer
Interventions
DRUG

Injection of 99mTc-NM-02

Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer

Trial Locations (1)

200080

Shanghai General Hospital, Shanghai

All Listed Sponsors
collaborator

NanoMab Technology (UK) Limited

INDUSTRY

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER